特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

代謝型グルタミン酸受容体3 (mGluR3、GRM3、GPRC1C、MGLUR3) :パイプライン製品の分析

Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 363127
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
代謝型グルタミン酸受容体3 (mGluR3、GRM3、GPRC1C、MGLUR3) :パイプライン製品の分析 Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 36 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートでは、代謝型グルタミン酸受容体3 (mGluR3、GRM3、GPRC1C、MGLUR3) の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなど、体系的な情報を提供しています。

目次

イントロダクション

概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療分野別
  • 開発中の製品:適応別

パイプライン製品の概要

  • 初期段階の製品

開発中の製品:企業別

開発中の製品:大学/研究機関別

治療薬の評価

  • 単剤/併用療法別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Addex Therapeutics Ltd
  • Domain Therapeutics SA
  • Medgenics, Inc.
  • Prexton Therapeutics SA
  • 大正製薬ホールディングス

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

最新ニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Addex Therapeutics Ltd, H1 2020
  • Pipeline by Denovo Biopharma LLC, H1 2020
  • Pipeline by Eli Lilly and Co, H1 2020
  • Pipeline by Mavalon Therapeutics Ltd, H1 2020
  • Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
目次
Product Code: GMDHC2429TDB

Summary:

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Metabotropic glutamate receptor 3 is a G protein-coupled receptor encoded by the GRM3 gene. L-glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. mGluR3 is expressed by glia and neurons in many brain regions and has a predominantly presynaptic distribution, consistent with its role as an inhibitory autoreceptor and heteroceptor. mGluR3 are coupled to Gi/o which inhibits adenylyl cyclase, decreasing the formation of cAMP.

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Depression, Schizophrenia, Anxiety Disorders, Cognitive Impairment, Drug Addiction, Neurodegenerative Diseases and Parkinson's Disease.

The latest report Metabotropic Glutamate Receptor 3 - Pipeline Review, H1 2020, outlays comprehensive information on the Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
  • The report reviews Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Overview
    • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Denovo Biopharma LLC
    • Eli Lilly and Co
    • Mavalon Therapeutics Ltd
    • Taisho Pharmaceutical Holdings Co Ltd
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Drug Profiles
    • DT-011088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3020371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGS-0274 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pomaglumetad methionil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Modulate mGlu3 Receptor for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0092273 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0650786 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Dormant Products
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Discontinued Products
  • Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 18, 2016: Domain Therapeutics and Medicxi launch Mavalon Therapeutics, aimed at halting the progression of Parkinson's disease
      • Apr 14, 2014: Domain Therapeutics continues program to alter course of Parkinson's disease with renewed support by The Michael J. Fox Foundation
      • Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
      • Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
      • Mar 29, 2009: Lilly Announces Inconclusive Phase II Study Results For mGlu2/3 At The International Congress On Schizophrenia Research
      • Sep 02, 2007: Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer